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a b s t r a c t
We reported previously on a vaccine approach that conferred apparent sterilizing immunity to
SIVsmE660. The vaccine regimen employed a prime–boost using vectors based on recombinant vesicular
stomatitis virus (VSV) and an alphavirus replicon expressing either SIV Gag or SIV Env. In the current
study, we tested the ability of vectors expressing only the SIVsmE660 Env protein to protect macaques
against the same high-dose mucosal challenge. Animals developed neutralizing antibody levels
comparable to or greater than seen in the previous vaccine study. When the vaccinated animals were
challenged with the same high-dose of SIVsmE660, all became infected. While average peak viral loads
in animals were slightly lower than those of previous controls, the viral set points were not signiﬁcantly
different. These data indicate that Gag, or the combination of Gag and Env are required for the
generation of apparent sterilizing immunity to the SIVsmE660 challenge.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Recent reports have demonstrated that “functional” cures for
HIV infection might sometimes be possible (Saez-Cirion et al.,
2013; Hutter et al., 2009). Cessation of antiretroviral therapy, with
or without allogeneic bone marrow transplantation, however,
often leads only to a delay in the rebound of viral loads (Henrich
et al., 2013; Persaud et al., 2013). Even if some individuals can
maintain control of their viral loads throughout their lifetime, the
limitations of using these strategies globally are apparent. Devel-
opment of a prophylactic vaccine is still an essential component of
any strategy to eradicate HIV infection worldwide.
Recombinant rhesus cytomegalovirus (RhCMV) vaccine vectors
expressing Gag, Pol, Env, and a Rev–Tat–Nef fusion protein have
been shown to induce immunity that can control and eventually
clear a pathogenic SIVmac239 challenge virus in roughly half of
the vaccinated rhesus macaques (Hansen et al., 2011; Hansen et al.,
2013). A variety of other vaccine vectors have also achieved
varying levels of apparent sterilizing protection in multiple low
dose challenges (Barouch et al., 2012; Patel et al., 2013; Flatz et al.,
2012; Letvin et al., 2011). Multiple low-dose challenge mo-
dels closely mimic a heterosexual exposure to HIV because of
the transmission of a small number of founder viruses from the
challenge stock (Keele et al., 2009; Li et al., 2010). In men who
have sex with men (MSM), however, multiple founder viruses are
often transmitted during the time of initial exposure (Li et al.,
2010; Tully et al., 2012). Since a greater number of founder viruses
are transmitted during a high-dose challenge, this model may
more accurately predict the efﬁcacy of vaccines to prevent the
transmission of HIV in MSM.
We previously described a vaccine regimen that resulted in
apparent sterilizing immunity to a high-dose mucosal challenge
with the pathogenic SIVsmE660 quasispecies. This vaccine used a
heterologous prime–boost vaccine strategy with vectors based on
recombinant vesicular stomatitis virus (VSV) and virus-like vesi-
cles (VLVs) derived from a Semliki Forest Virus (SFV) replicon
packaged with VSV G (SFV-G). These vectors encoded Gag and Env
proteins derived from the SIVsmE660 viral swarm (Schell et al.,
2011). Four out of six animals challenged never showed detectable
viral loads, and the two that were infected rapidly controlled their
viral loads to below the limit of detection. Control of viral loads in the
infected animals was mediated by CD8þ T cells, as evidenced by the
rebound in viral loads when CD8þ T cells were depleted from these
animals (Schell et al., 2011). The 4 protected animals showed no
rebound in viral loads upon CD8þ T cell depletion implying that the
vaccine generated sterilizing immunity. These animals had high
neutralizing antibody (nAb) to E660 Envs prior to challenge, but
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only marginal or undetectable CD8þ T-cell responses to Env and
Gag. These results suggested that antibody to Env might be
sufﬁcient for protection. Therefore, in the current study, we asked
if the same vaccine regimen expressing Env alone would generate
similar sterilizing immunity.
Results
Rechallenge of protected animals
We decided to ﬁrst test if the previously protected animals
would maintain their sterilizing immunity against an additional
high-dose mucosal challenge with SIVsmE660 (Schell et al., 2011;
Schell et al., 2012). Because of the high titers of neutralizing
antibodies, and relatively low levels of cell-mediated responses
produced by these animals, we suspected that the sterilizing
protection seen was antibody mediated. Therefore, prior to the
re-challenge (650 days after the initial challenge), the protected
animals received a boost with a recombinant VSV vector expres-
sing an SIVsmE660 Env protein that has its cytoplasmic domain
replaced with the cytoplasmic domain of VSV G (EnvG). A full
historical timeline for these animals is shown in Fig. 1A. The boost
increased neutralizing antibody titers to the tier 1 Env, E660.11, as
well as two transmitted founder virus Envs (DF38.21.33C and
EN82.57C) in each animal to levels higher than those at the time
of initial challenge (Fig. 1B). Only one animal, CM17 showed high
levels of Env responsive PBMCs at the time of boost (Fig. 1C) as
assayed by IFN-γ ELISPOT. After the boost, two animals, CJ98 and
DT03, showed an increase in the numbers of circulating Env
responsive PBMCs. Only one animal, CJ98, showed an appreciable
level of Gag responsive circulating PBMCs at the time of re-
challenge (Fig. 1D). The animals were re-challenged with the
original stock of SIVsmE660 at a high dose (TCID50¼4000) and
all remained protected (Fig. 1E).
Vaccination schedule, SIVsmE660 challenge, and plasma viral loads of
naïve animals
We next wanted to test the hypothesis that the sterilizing
protection we previously demonstrated for a VSV/SFV-G hetero-
logous prime boost vaccine regimen (Schell et al., 2011; Schell
et al., 2012) was provided by the high level of neutralizing
antibodies to Env induced by the vaccine. Eight rhesus macaques
that lacked SIVsmE660-restrictive Trim 5α TFP/CypA (Reynolds et
al., 2011) and MHC alleles were selected for the study. Their
genotypes are shown in Table 1. The vaccination scheme was the
same as in the previous study (Schell et al., 2011), except that we
omitted vectors encoding Gag (Fig. 2A). Animals were primed (day
0) with a VSV vector expressing an SIVsmE660 Env protein that
has its cytoplasmic domain replaced with the cytoplasmic domain
of VSV G (EnvG). They were boosted with the SFV-G virus-like
vesicle (VLV) vector encoding EnvG (day 56) and then given a
second boost with a VSV vector encoding EnvG (day 119).
The animals were then challenged intrarectally at day 147 with the
same high dose (TCID50¼4000) of the SIVsmE660 quasispecies used
above and in the previous study (Schell et al., 2011; Schell et al., 2012).
As shown in Fig. 2B, all eight animals became infected after the
challenge. Average plasma viral loads for the previously published
vaccine and control groups are compared in Fig. 2C. The Env-only
(Fig. 2C, green line) vaccine regimen tested here suppressed peak viral
loads about 10-fold, but the peak loads were about 10-fold higher than
the infected animals from the previous GagþEnv vaccine group
(Fig. 2C, red line). None of the animals in the Env-only vaccine group
controlled their infection, and their viral set points were even slightly
higher than control animals (Fig. 2C, blue line).
ELISA titers of gp140 speciﬁc antibodies
To determine if the animals receiving the Env-only vaccine
generated levels of Env-speciﬁc antibodies comparable to ani-
mals from the previous study using Env and Gag antigens (Schell
et al., 2011), we initially performed ELISA assays using sera
collected at the day of challenge and 28 days post-challenge. At
the time of challenge, the animals that received the Env-only
vaccine (Fig. 3, left panel) generated comparable or higher titers
of antibodies to gp140 to those that received the GagþEnv
vaccine (Fig. 3, right panel). The average titers were signiﬁcantly
higher in the Env-only group (po0.04). Consistent with the
animals from the Env-only vaccine group becoming infected, all
showed an anamnestic antibody response to gp140 28 days
post-challenge. Only those animals that were not protected
from infection in the previous GagþEnv vaccine study (DF38
and DG21, denoted by an asterisk in Fig. 3, right panel) showed
an anamnestic antibody response.
The Env-only vaccine generated high titers of neutralizing antibodies
We next tested the ability of the sera from the Env-only vaccine
animals to neutralize an SIV envelope from the viral swarm (E660.11),
and transmitted/founder (T/F) envelopes isolated from infected ani-
mals from a previous study (EN82.57C and DF38.21.33C) (Schell et al.,
2011). As shown in Fig. 4A, animals from the Env-only vaccine group
had neutralizing antibodies (nAbs) against the tier 1 E660.11 envelope
by the time of the ﬁrst boost (day 56). Following the boost with the
VLV-EnvG vector E660.11 at day 56, nAbs titers rose approximately
100-fold by day 119. The ﬁnal VSV boost at day 119 did not increase
the titers of nAb against E660.11.
When the Env-only animals were compared to the previous
GagþEnv animals, similar neutralization titers against E660.11
were seen over the vaccination course. In Fig. 4D, the average
neutralization of E660.11 envelope is shown for the Env-only
(green line) and GagþEnv vaccinated animals. The GagþEnv
group was divided into protected (orange line) and infected (red
line) animals. By the time of the VSV boost (day 119), the Env-only
animals had developed signiﬁcantly higher titers of nAbs against
E660.11 envelope than either the protected or infected animals of
the GagþEnv group as determined by a two-tailed T test
(po0.0006 and po0.02, respectively). This signiﬁcant difference
in nAb titers between the two groups was maintained through the
day of challenge (day 147). Only those animals that were unpro-
tected (green and red lines) showed an anamnestic nAb response
after the challenge.
Table 1
Genotypes of animals in the Env-only study. The sex of each animal is denoted in
parentheses.
Animal
ID
A01 A02 A08 A11 B01 B03 B04 B08 B17 DRB*
w201
Trim
5α
BJ42 (M)  þ         TFP/
TFP
BV15
(M)
  þ        TFP/Q
CC61
(M)
       þ   TFP/Q
CD71
(M)
   þ      þ TFP/Q
CK48 (F)           TFP/Q
CR43 (F)           TFP/Q
DR07 (F)   þ  þ     þ TFP/Q
EL27 (F)  þ         TFP/Q
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Fig. 1. Re-challenge of protected animals. (A) Complete vaccination and challenge history of the protected animals. The G serotype of the vector is indicated within parentheses:
Indiana (I), New Jersey (NJ), or Chandipura (Ch). The route of immunization is also indicated: intramuscular (IM) or intranasal (IN). (B) Neutralizing antibody titer of SIVsmE660
envelopes on the day of ﬁrst (white bars) and second (black bars) challenge. The three envelopes tested, E660.11 (left), DF38.21.33C (center), and EN82.57C (right) are indicated. IFN-
γ by PBMCs is shown in response to the Env (C) and Gag (D) vaccine antigens. The days of boost and re-challenge are indicated by the black and red arrows, respectively. (D) Plasma
viral RNA loads for the re-challenged animals. All animals remained protected against a second high dose challenge. Average control viral loads shown in orange for reference.
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We also tested the ability of the sera from the Env-only animals
to neutralize two T/F virus envelopes isolated from an infected
control animal (EN82), and a GagþEnv vaccinated animal that
became infected (DF38) (Schell et al., 2011). The two T/F envelopes,
DF38.21.33C and EN82.57C, are more difﬁcult to neutralize than
E660.11 (Fig. 4A–C). The serum nAb titers against both DF38.21.33C
(Fig. 4B) and EN82.57C (Fig. 4C) averaged about 10-fold lower than
those against E660.11 on the day of challenge. Consistent with the
results from the E660.11 neutralization, the Env-only vaccine
regimen elicited higher average levels of nAb against both the
DF38.21.33C and EN82.57C envelopes, than did the GagþEnv
vaccine regimen (Fig. 4E and F).
Antibody speciﬁc for the gp120 V2 loop does not correlate with
protection
Previous SIV vaccine studies have shown a correlation between
V2 loop-binding antibodies and vaccine protection (Barouch et al.,
2012; Rolland et al., 2012). We therefore determined if either
vaccine regimen, GagþEnv or Env-only, elicited V2-binding anti-
bodies, and if they correlated with protection. Following the
approach used by others (Barouch et al., 2012), we used a
synthetic, cyclized V2 loop corresponding to the amino acid
sequence present in the vaccine envelope. Day of challenge
antibody binding to this synthetic V2 loop was then measured
by surface plasmon resonance (SPR) for each animal. Antibody
binding to the cyclized V2 peptide, presented as response units
in Fig. 5A (n¼4), was higher in most animals that received the
Env-only vaccine as compared to those that received the
GagþEnv vaccine. The average response for each group is
shown in Fig. 5B. Although the Env-only group had higher
average IgG binding to the peptide, this antibody did not confer
protection from infection. The lack of correlation with
Fig. 2. Vaccination schedule and plasma virus loads. (A) Vaccination schedule with vectors expressing Env alone for the eight naïve macaques. The G serotype of the vector is
indicated within parentheses. Animals were challenged rectally with a high dose (TCID50¼4000) of the SIVsmE660 viral stock at day 147. (B) Plasma virus loads for individual
animals in the current study. (C) Average plasma virus loads for Env-only vaccine group animals in the current study (green); the fully protected animals (orange) or infected
animals (red) from the previous GagþEnv vaccine study (Schell et al., 2011) and unvaccinated control animals (blue).
Fig. 3. Anti-gp140 serum antibody titers. Serum antibody titers from the day of original
challenge (black bars) and 28 days post-challenge (striped bars) are shown for each
animal. Sera from animals that received the Env-only (left panel), and those that received
the combination GagþEnv (right panel) were tested in parallel. Animals DF38 and DG21
were infected in the original study and are denoted by asterisks. The reciprocal serum
dilution that gave a reading of O.D.¼0.2 was used as the endpoint for deﬁning the titer.
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protection is also clear when the mean V2 Ab binding of the ﬁve
protected and ten unprotected animals from the GagþEnv and
Env-only groups are compared (Fig. 5B). No animals from either
group showed anti-V2 serum IgA binding.
Cellular interferon gamma response to the Env vaccine antigen
To determine if the Env-only vaccine induced a cellular
immune response to the SIV envelope, we used an ELISPOT assay
to measure IFN-γ produced in response to the Env antigen. The
responses of individual animals are shown in Fig. 6A. Five out of
eight of the animals generated signiﬁcant cellular immune
responses to the vaccine Env antigen. These responses were higher
than we saw previously for the animals given the GagþEnv
vaccine, shown in Fig. 6B and (Schell et al., 2011) we also did not
observe any correlation between the cellular immune response to
Env and the viral loads. The Env-only animals did not show IFN-γ
responses to the cloned E660 Gag antigen used in the previous
studies (data not shown).
Discussion
We have demonstrated that a heterologous prime–boost vaccine
based on VSV and hybrid SFV–VSV (SFV-G) virus-like vesicle vectors
could provide sterilizing immunity to a high-dose mucosal challenge
with SIVsmE660 (Schell et al., 2011; Schell et al., 2012). The vectors
encoded Gag and Env proteins derived from the SIVsmE660 viral
swarm. We hypothesized, based on the immune responses detected,
that the protection could be due to Env neutralizing antibodies
preventing infection. Therefore, we boosted the previously protected
animals from the prior study (Schell et al., 2011; Schell et al., 2012)
with a recombinant VSV vector expressing Env alone almost two
years after the original challenge (Fig. 1A). By the day of re-challenge,
the boost had increased neutralizing antibodies against the tier 1 Env,
E660.11, as well as two T/F virus Envs from the original study to titers
higher than that seen on the day of the ﬁrst challenge (Fig. 1B). Only
one animal, CM17, showed high numbers of PBMCs that produced
IFN-γ to Env antigen at the time of boost. After the boost, two
additional animals showed Env responsive PBMCs. The decrease in
Env responsive PBMCs in animal CM17 most likely represented an
efﬂux of these cells into the tissues and lymph nodes after the boost
(Fig. 1C). Every animal remained completely protected against a
second high dose mucosal challenge, TCID50¼4000 (Fig. 1E).
To determine if the protection was due to immune responses to
Env alone, we vaccinated eight rhesus macaques with the same
VSV and SFV-G vectors encoding only the recombinant Env gene.
We found that this “Env-only” vaccine did not provide protection
because all animals became infected and had viral set-points
comparable to previously infected animals that did not control
their loads (Fig. 2) (Schell et al., 2011; Schell et al., 2012).
The Env-only vaccine generated signiﬁcantly higher levels of
pre-challenge Env speciﬁc antibodies than the GagþEnv vaccine,
as measured by ELISA (Fig. 3). The Env-only vaccine regimen also
Fig. 4. Neutralization of SIVsmE660 envelopes. Serum samples from animals that received the Env-only vaccine and serum samples from the GagþEnv vaccine study were
tested for their ability to neutralize pseudovirions carrying different Env proteins derived from the viral swarm or founder viruses from infected animals (Schell et al., 2011).
Pre-and post-challenge serum nAb titers for individual animals in the Env-only vaccine group using Envs E660.11 (A), DF38.21.33C (B) and EN82.57C (C). For each Env tested,
a comparison of the average neutralizing titers from the Env-only group in the present study (green), and the previous GagþEnv vaccine group (orange, protected animals;
red, infected animals) are shown in panels D–F. Days of vaccine boosts (black arrows), and the day of challenge (red arrows) are indicated.
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elicited higher levels of nAbs to the tier 1 E660.11 Env, and to two
harder to neutralize T/F Envs (Fig. 4) isolated from infected
animals in our previous study (Schell et al., 2011). By the day of
challenge (147 days post-prime), the Env-only vaccine recipients
had signiﬁcantly higher average serum nAb against E660.11,
DF38.21.33C, and EN82.57C when compared to the serum from
either the infected or protected animals from the GagþEnv study
(Fig. 4D–F). While we did see low levels of nAb against the more
difﬁcult to neutralize tier 2 Env CR54PK.2A5 in the sera of animals
from the Env-only group, none neutralized to the 50 percent
threshold (Schell et al., 2012) (data not shown). The higher anti-
body responses most likely resulted from employing the same
total vector titers in prime and boosts, while eliminating the
vectors expressing Gag. This eliminates competing response to
Gag while doubling the Env vector dose. Both Gag and Env
expressing vectors replicate to similar titers and expressed similar
amounts of protein (data not shown).
Although V2-loop binding antibodies correlated with protec-
tion against a low-dose SIVmac251 heterologous challenge model
for an adeno/poxvirus based vaccine (Barouch et al., 2012), we did
not see a correlation between the presence of V2-binding anti-
bodies and protection in our high-dose challenge model employ-
ing a viral swarm. The Env-only vectors generated similar or
higher levels of V2-binding antibodies in most animals than in
those that received the GagþEnv vectors (Fig. 5). V2-binding
antibodies might be important for protection in low-dose hetero-
logous challenges (Barouch et al., 2012), or during the course of
some natural exposures (Gottardo et al., 2013; Zolla-Pazner et al.,
2013), but might not be effective during a high-dose challenge.
Roederer et al. have recently reported a four amino acid
signature within the C1 domain of SIVsmE660 Env that correlated
with neutralization sensitivity (VTRN) or resistance (IAKN) of
transmitted/founder (T/F) viruses (Kwong and Mascola, 2012). In
our previous GagþEnv vaccine study we saw transmission of only
the sensitive VTRN signature in the single T/F virus Env sequences
found in the only two infected animals, DG21 and DF38 (accession
numbers KM496659-KM496961), in the vaccine group (Schell
et al., 2011; Trkola et al., 2005). We have not yet performed the
single genome ampliﬁcation and sequence analysis from the
animals in this Env-only vaccine study to determine if there was
any selection for neutralization resistant viruses. Both cloned
founder virus Envs (EN82.57C and DF38.21.33C) used in this study
have neutralization sensitive C1 amino acid signatures, VTRS and
VTRN, respectively.
Even though the Env vectors generated high levels of nAb
against tier 1 Envs, they did not elicit broadly nAbs against
heterologous Envs (data not shown). Recent published studies
have shown that the generation of broadly nAbs is slow to develop
in infected patients because of the extent of hypermutation
Fig. 5. Anti-V2 loop IgG antibodies. (A) Sera from animals of the Env-only group,
GagþEnv group, or pooled sera from unvaccinated animals were tested for their
ability to bind a cyclized V2 peptide using surface plasmon resonance. Infected
animals are represented by black bars. The animals protected in the previous
GagþEnv study are represented by striped bars. The data shown are averaged
binding response units collected for each serum sample on two cells of a CM5 chip
containing the V2 peptide, during two separate experiments (n¼4); error bars
represent single standard deviations. (B) The average binding response for each
vaccine group, and for protected or infected animals combined from both studies is
represented.
Fig. 6. Cellular immune responses to Env. IFN-γ ELISPOT assay of SIV Env speciﬁc responses for all animals in the Env-only (A) and GagþEnv (B) groups. Data are represented
as spot forming cells (SFC) per 1106 cells. Arrows represent times of priming and boosting vaccinations (black) and day of challenge (red). Asterisks denote the two animals
in the GagþEnv group from the previous study that were infected.
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required to modify the germline sequence (Kwong and Mascola,
2012). Broadly nAbs can act as a therapeutic in controlling an
established infection in both humans and macaques (Trkola et al.,
2005; Barouch et al., 2013). Enhancing the immunogenicity of Env
(Kumar et al., 2013; Kassa et al., 2013), or designing innovative
strategies to produce and deliver broadly nAbs (Barouch et al.,
2013; McCoy et al., 2012; Abdel-Motal et al., 2011; Balazs et al.,
2013; Shingai et al., 2014) are alternative strategies for vaccination.
We also noted an increase in cellular immune responses to Env
in this study compared the EnvþGag study (Fig. 6). This increase
could again be due to the increased Env vector titer, but also to
lack of competition from immunodominant Gag epitopes. It has
been reported that CD8þ T cell responses to immuno-dominant
SIV Gag epitopes are capable of suppressing responses to Env
(Manuel et al., 2009).
Our results indicate that vectors encoding Gag are a critical
component of our vaccine that provides sterilizing protection
against high dose mucosal challenge with SIVsmE660. It is
certainly possible that undetected mucosal cellular immune
responses to Gag rather than antibody to Env were important in
the vaccine protection (Hansen et al., 2013). To determine if there
is some synergy between Gag and Env immune responses in the
protective vaccine, it will now be critical to determine if Gag alone
can provide the same level of protection as GagþEnv. These
experiments could be informative for design of future clinical
trials of HIV vaccines.
Materials and methods
Animals, vaccination dosage, and sample preparation
In the current study, ﬁve previously protected and eight naïve
Indian-origin rhesus macaques were enrolled. Of the protected
animals, animal EF30 received a VSV vector expressing granulo-
cyte macrophage colony stimulating factor at the time of prime
(Schell et al., 2012), and the other four, CJ98, CM17, DT03, and FP72
(Schell et al., 2011) did not. The eight naïve macaques were
selected based on their lack of restrictive Trim 5α and MHC class
I genotypes (Table 1). All animals were negative for serum
antibodies to herpes B virus, SRV, and simian T-lymphotropic
virus. The naïve animals were negative for serum antibodies to
simian immunodeﬁciency virus (SIV). The animals were fed and
housed according to regulations set forth by the Guide for the Care
and Use of Laboratory Animals (Henrich et al., 2013) and the
Animal Welfare Act at the Tulane National Primate Research
Center (TNPRC). All animals were born and raised at the TNPRC.
Every procedure was approved by the TNPRC Institutional Animal
Care and Use Committee and was in accordance with the Guide for
the Care and Use of Laboratory Animals and the Animal Welfare
Act. The TNPRC maintains an AAALAC-I accredited animal care and
use program. The animals are maintained on a 12 h light/dark
cycle and fed a commercially available nonhuman primate chow
twice daily and water is available ad libitum. Nonhuman primate
animal rooms are maintained at a temperature of 64–84 F with a
humidity range of 30–70%. The rooms are provided 10–15 fresh air
changes per hour. All animals receive enrichment as part of the
TNPRC Policy on Environmental Enrichment. Enrichment includes
durable and destructible objects in their cage, perches, various
food supplements (fruit, vegetables, treats) foraging or task-
oriented feeding methods fed a minimum of three times weekly,
and human interaction with caretakers. Animals are observed
twice daily by care staff and a veterinarian is notiﬁed if abnorm-
alities are present. Procedures were conducted with the use of
ketamine hydrochloride (10 mg/kg intramuscularly; Ketaset, Fort
Dodge Laboratories). Animals are administered buprenorphine
hydrochloride (0.03 mg/kg intramuscularly twice daily; Buprenex,
Reckitt & Colman) for any procedures expected to induce pain or
distress. Tissue and serum samples were shipped cryogenically
frozen to Yale University and were stored in liquid nitrogen upon
arrival.
Because vaccines generally develop a strong neutralizing anti-
body against the VSV glycoprotein (G), our vaccine regimen
employs glycoprotein exchange vectors (Rose et al., 2000), the
serotypes of which are indicated in parentheses at the time of
prime and boosts in Figs. 1A and 2A. For the re-challenge experi-
ments, the animals were boosted with a Chandipura (Ch) glyco-
protein exchange VSV vector expressing the E660 Env only, VSV
(Ch)-EnvG (Rose et al., 2000). Animals received a total of 1108
VSV plaque forming units (PFU)—6107 PFU intramuscularly (IM)
and 4107 intranasally (IN) per vaccination. The previously
published vaccine schedule (Schell et al., 2011) was used for the
naïve animals. As before, the SFV-G VLV boosting vectors were
delivered IM at a concentration of 1107 infectious units (IU) per
animal. Animals were challenged intrarectally with the same stock
of SIVsmE660 at a high titer (TCID50¼4000). Quantitative PCR of
plasma viral RNA was conducted by the University of Wisconsin
core facility.
Neutralization assays, gp140 ELISAs, and ELISPOT assays
The methods used to measure serum antibody and cellular
immunity have been reported previously (Schell et al., 2011). For
the neutralization assays, TZM-bl cells and plasmids for generating
the HIV pseudoviruses were kindly provided by David Monteﬁori
(Duke University, Durham, NC). The target vaccine SIVsmE660
gp140 antigen used for ELISAs was generated using a recombinant
vaccinia virus (rVV) encoding the EnvG gene (Blasco and Moss,
1995). The rVVs expressing the full-length SIVsmE660 vaccine
antigens used in the ELISPOT assays were also generated using this
system. Plasmids and small plaque forming vaccinia virus (Rb12)
used to generate rVVs were kindly provided by Bernard Moss.
Codon-optimized genes encoding founder virus Envs EN82.57C
and DF38.21.33C (Schell et al., 2011) were synthesized by Gen-
script (Piscataway, NJ) and have been deposited in GenBank
(accession numbers KJ130318 and KJ130319, respectively).
Surface plasmon resonance
Binding studies were performed at 25 1C, as described by
others (Pegu et al., 2013), using a Biacore T100 optical biosensor
equipped with a CM5 research-grade sensor chip (GE HealthCare,
Biacore). Neutravidin was amine-coupled to approximately 15,000
response units (RU) on the CM5 chip. A synthetic peptide of the V2
loop sequence present in the vaccine (CIKNNSCAGLEQEPMIGCKFN-
MTGLKRDKRIEYNETWYSRDLICEQSANESESKCY) was generated, bioti-
nylated, and cyclized under thermodynamically controlled condi-
tions by JPT peptides (Berlin, Germany). The peptide was captured
to 1000–3000 RUs on cells 3 and 4 of the chip. Cell 2 was used as a
Neutravidin-biotin negative control to assess the quality of refer-
encing. Loosely associated peptides were removed from the chip
by an injection of 10 mM HCl. Unbound biotin was saturated with
amino-PEG-biotin (Pierce Biotechnology Inc.) and rinsed with
10 mM HCl. Sera diluted 50-fold in running buffer (25 mM Tris,
137 mM NaCl, 0.05% Tween 20, pH 7.4) were injected for 240 s
(s) at a ﬂow rate of 30 mL/min. After 60 s of dissociation time, anti-
rhesus IgG or IgA secondary antibodies (20 mg/mL) were injected
for 120 s (10 ml/min). The chip was regenerated by subsequent
injections of 50 mM HCl and EDTA, each for 30 s at 30 ml/min,
followed by an injection of running buffer for 60 s at 30 ml/min.
The level of serum anti-V2 antibody was estimated as the
amplitude of the binding of anti-isotype antibody (anti-IgG or
J.B. Schell et al. / Virology 476 (2015) 405–412 411
-IgA) captured during injection of the diluted macaque sera. The
anti-serotype binding responses were double-referenced against
nonspeciﬁc binding to neutravidin alone (cell 1) and responses
generated by injections of buffer rather than diluted sera.
Statistical analysis
Data were analyzed by performing a two-tailed T test with the
statistical analysis software Prism 6 (GraphPad).
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